Is Manipal Health Enterprises IPO Good or Bad – Detailed Review

Manipal Health Enterprises Limited’s IPO is set to open its initial public offering from July 29, 2026, to July 31, 2026. When considering applying for this IPO, potential investors might have questions about whether the Manipal Health Enterprises IPO is a good investment and if it's worth subscribing to.

This article provides a comprehensive analysis of Manipal Health Enterprises's IPO, covering its business operations and a fundamental analysis of its RHP to help you make an informed investment decision.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.

Manipal Health Enterprises IPO Review

Manipal Health Enterprises Limited IPO is open for subscription from July 29, 2026, to July 31, 2026, with listing expected on August 05, 2026, on NSE and BSE.

The company operates an advanced healthcare setup consisting of 49 hospitals (43 owned and six managed under operation and management agreements) with 13,037 licensed beds across 14 states and union territories in India, alongside 21 clinics and 102 ambulances under the Manipal Ambulance Response Service (MARS). 

The company's origins trace back to the establishment of its flagship hospital in Bengaluru in 1991, and it was formally incorporated under its corporate framework in 2010.

The company provides a comprehensive range of clinical care services from outpatient consultations to complex tertiary and quaternary care interventions.

As of the fiscal year ended March 31, 2026, the company reported a consolidated revenue from operations of Rs 10,335.75 crore (Rs 10,935.62 crore on a pro forma basis), maintaining its position as India's largest multispecialty hospital group by bed capacity.

The company’s operations are regionally diversified, with hospital facilities located across key economic clusters: Karnataka accounted for 46.40% of operational revenue in FY26, Eastern India (West Bengal, Odisha, Jharkhand, Sikkim) accounted for 22.42%, Rest of India (Delhi, AP, Rajasthan, UP, Haryana, Punjab, Tamil Nadu) accounted for 19.66%, and Maharashtra & Goa accounted for 11.52%.

Its revenue from operations stood at Rs 6,171.63 crore in FY24 (consolidated restated), grew to Rs 8,242.25 crore in FY25 (consolidated), and reached Rs 10,335.75 crore in FY26 (consolidated), representing a 29.41% CAGR over the period.

For the year ended March 31, 2026, the company reported a Profit After Tax (PAT) of Rs 916.52 crore. This follows a net profit of Rs 1,081.67 crore in FY25 and Rs 533.20 crore in FY24.

The company maintains a strong consolidated EBITDA margin (excluding exceptional items) of 27.05% in FY26, 27.26% in FY25, and 28.79% in FY24.

Key strengths include its position as India's largest multispecialty hospital group by bed capacity, leadership in three key metro markets (Bengaluru, Kolkata, and Pune), strong clinical focus on high-acuity CONGO-R specialties, a proven and repeatable playbook for integrating transformative acquisitions, and an experienced management team backed by marquee global institutional investors.

Primary risks include geographical revenue concentration in Karnataka (46.40% of revenue in FY26), dependency on health insurance companies and third-party administrators (TPAs) for payment collections (49.68% of gross inpatient revenue in FY26), intense competition for medical talent and high nurse attrition (19.56% in FY26), exposure to medical negligence and regulatory litigations, and integration challenges associated with newly acquired hospital networks.

The book-built issue consists of a Fresh Issue of up to Rs 8,000.00 crore and an Offer for Sale worth Rs 1,275 crore, the proceeds of OFS will be received by the Selling Shareholders.

Shares are priced in the Manipal Health Enterprises IPO price band of Rs 560 to Rs 590 per share, with a minimum lot size of 25 shares.

Company Overview of Manipal Health Enterprises IPO

Manipal Health Enterprises Limited operates a pan-India network of multispecialty hospitals delivering comprehensive healthcare services across preventive, curative, tertiary, and quaternary care.

The company serves millions of patients annually, handling 5.27 lakh inpatient discharges and 54.83 lakh outpatient footfalls in FY26 across 42 clinical specialties.

Instead of focusing solely on secondary care, Manipal Health Enterprises emphasizes high-acuity specialty care centered around six core areas: 

• Cardiac Sciences

• Oncology

• Neurosciences

• Gastro Sciences

• Orthopedics

• Renal Sciences

Their modern clinical facilities feature advanced medical technologies, including 18 soft tissue surgical robots, 23 orthopedic and spine surgical robots, 19 linear accelerators (LINACs), two tomotherapy units, 58 catheterization labs, 44 MRI scanners, and 15 PET-CT scanners.

Patients and referring physicians choose Manipal Health Enterprises for complex surgical procedures, organ transplants, precision oncology, robotic-assisted spine and joint surgeries, and 24/7 emergency critical care across India.

Manipal Health Enterprises Business Segments

The company generates its inpatient revenue primarily through six high-acuity specialties (CONGO-R) and other general and surgical specialties:

Others include internal medicine, General Surgery, Pediatrics, Critical Care, etc.

Company’s Management

The company is led by an experienced professional management team with extensive domain experience in hospital operations and healthcare delivery.

The Board is headed by Dr. Hebri Sudarshan Ballal (Chairman and Non-Executive Director), supported by Executive Director Dilip Jose Puthiyidathu (Managing Director and Chief Executive Officer) and Non-Executive Directors Dr. Ranjan Ramdas Pai, Ravi Lambah, Ved Kalanoria, Puneet Bhatia, Vinesh Kumar Jairath, Subramaniam Somasundaram, and Revathy Ashok.

The financial, administrative, operational, and legal activities are overseen by Sameer Agarwal (Group Chief Financial Officer), Karthik Rajagopal (Chief Operating Officer), and Sathish Kolar Ramamoorthy (General Counsel, Company Secretary, and Compliance Officer).

Industry Overview of Manipal Health Enterprises IPO

Manipal Health Enterprises Limited operates within the Indian healthcare delivery market, which encompasses private and government multispecialty hospitals, diagnostic chains, and outpatient clinics.

This sector is witnessing strong growth driven by an aging demographic, rising incidence of non-communicable chronic diseases, expanding private health insurance coverage, growing medical value travel, and higher disposable household incomes.

Despite this growth potential, the industry faces structural constraints, including low bed density (16 beds per 10,000 population in India versus the global median of 33 beds), shortages of specialized medical professionals, price ceiling regulations on essential drugs and medical devices, and regulatory compliance demands across multiple jurisdictions.

Industry statistics are sourced from the Manipal Health Enterprises Limited Red Herring Prospectus (RHP) dated July 23, 2026.

Financial Overview of Manipal Health Enterprises IPO

Note: Calculated on a restated and consolidated basis in accordance with Ind AS.

• Revenue from Operations: Consolidated revenue from operations grew significantly by 25.40% from Rs 8,242.25 crore in FY25 to Rs 10,335.75 crore in FY26, driven by higher inpatient volumes, expansion in bed capacity, and the strategic acquisition of the Sahyadri Hospitals network.

• EBITDA Margin: Core operating profitability remained strong at 27.05% in FY26, 27.26% in FY25, and 28.79% in FY24, supported by higher complex case mix (CONGO-R) and operational cost discipline.

• Profit After Tax (PAT): Net profit stood at Rs 916.52 crore in FY26 compared to Rs 1,081.67 crore in FY25 and Rs 533.20 crore in FY24. The FY26 bottom-line was impacted by exceptional charges related to labor code implementation provisions and expansion expenses.

• Return on Net Worth (RoNW): RoNW stood at 10.57% in FY26, compared to 18.16% in FY25 and 14.75% in FY24, reflecting changes in the equity capital base post-acquisitions and corporate restructuring.

• Return on Capital Employed (RoCE): RoCE reached 21.88% in FY26 from 26.98% in FY25 and 27.74% in FY24, indicating healthy returns on capital deployed across operating hospital clusters.

• Net Debt to Adjusted EBITDA: The leverage ratio stood at 3.74x as of March 31, 2026, up from 2.00x in FY25, primarily due to non-convertible debentures issued to finance the acquisition of Sahyadri Hospitals, which are slated for repayment using IPO proceeds.

Financial figures are sourced from the Manipal Health Enterprises Limited Red Herring Prospectus (RHP) dated July 23, 2026.

Strengths and Risks of Manipal Health Enterprises IPO

Let's examine the strengths and weaknesses to determine whether the Manipal Health Enterprises IPO is good or bad for investors.

Strengths

• Largest Multispecialty Hospital Group in India: Holds the position of India's largest multispecialty hospital network by bed capacity with 13,037 licensed beds across 49 hospitals as of March 31, 2026.

• Leadership in Three Key Metro Markets: Only private hospital chain in India leading in three major metro clusters, Bengaluru, Kolkata, and Pune, by bed capacity, allowing local access and strong regional brand equity.

• High-Acuity CONGO-R Focus: Strong clinical emphasis on high-margin, complex specialties (Cardiac, Oncology, Neuro, Gastro, Orthopedics, and Renal) which contributed 64.30% of gross inpatient revenue in FY26.

• Proven Acquisition Integration Playbook: Track record of successfully acquiring, turning around, and scaling hospital chains, including Columbia Asia, Vikram Hospital, AMRI, Medica Synergie, and Sahyadri Group.

• Experienced Management & Marquee Shareholders: Backed by prominent global institutional investors like Temasek, TPG, and Novo Holdings, providing strong corporate governance and strategic alignment.

Risks

• Geographic Revenue Concentration: Derived 46.40% of total operational revenue in FY26 from hospitals located in Karnataka, exposing operations to regional economic or policy disruptions.

• High Reliance on Insurance and TPAs: Derived 49.68% of gross inpatient revenue in FY26 from insurance companies and TPAs; delays or disputes in claim settlements could impact working capital.

• Human Capital & Talent Retention: High competition for experienced specialist doctors and significant turnover among nursing staff (19.56% nurse attrition in FY26) could increase operating expenses.

• Exposure to Medical Negligence Claims & Litigations: Subject to risks of medical malpractice litigation, regulatory notices, and pending tax proceedings that could impact financial position and brand reputation.

• Gestation Risks of Greenfield & Brownfield Expansions: Planned addition of over 2,400 beds through greenfield and brownfield projects involves long gestation periods and capital expenditure before achieving optimal occupancy.

Strategies of Manipal Health Enterprises IPO

• Organic Network Expansion: Drive occupancy rates across existing hospitals while executing brownfield additions (around 483 beds) and greenfield project expansions (around 1,943 beds) by FY30 to strengthen core regional presence.

• Strategic Acquisitions: Pursue selective inorganic growth opportunities in key regional markets to enter new geographies and consolidate leadership, leveraging a proven integration playbook for clinical and operational turnaround.

• Digital & Technology Leverage: Scale digital channels, AI-assisted operational tools (such as step-down ICUs and automated nursing handovers), telehealth, and e-pharmacy services to extend patient reach, enhance clinical workflows, and drive operating efficiencies.

• Talent Attraction & Retention: Build a robust talent pipeline of specialist doctors and nurses by expanding academic pathways, residency programs, nursing partnerships, and structured career development.

• Advanced Infrastructure Investment: Continuously invest in state-of-the-art medical equipment, including soft-tissue and spine surgical robots, linear accelerators, tomotherapy, and advanced neurosurgery capabilities while strengthening in-house research.

Manipal Health Enterprises IPO vs. Peers

The RHP provides a comparative framework of Manipal Health Enterprises Limited against the listed Indian peers:

The listed peer groups are:

Apollo Hospitals Enterprise, Fortis Healthcare and Max Healthcare Institute.

The following securities mentioned are for comparative purposes only and do not constitute a recommendation to buy or sell.

• Revenue from Operations: While Apollo Hospitals Enterprise Limited (Rs 25,228.50 crore) operates at a significantly larger scale, Manipal Health Enterprises Limited (Rs 10,335.75 crore in FY26) represents a leading multispecialty hospital network comparable in scale to Max Healthcare Institute Limited (Rs 10,065.00 crore) and ahead of Fortis Healthcare Limited (Rs 9,127.84 crore).

• Operating EBITDA Margins: Manipal Health Enterprises Limited maintains strong operational profitability with an EBITDA margin of 25.58% in FY26, closely matching Max Healthcare Institute Limited (26.20%) and outperforming Fortis Healthcare Limited (23.40%) and Apollo Hospitals Enterprise Limited (14.90%).

• Return on Net Worth (RoNW): Backed by efficient capital deployment, Manipal Health Enterprises Limited recorded a Return on Net Worth of 10.57% in FY26 (18.16% in FY25), while its Return on Capital Employed (RoCE) of 21.88% matched Max Healthcare Institute Limited (21.80%) and closely trailed Apollo Hospitals Enterprise Limited (23.70%).

Objectives of Manipal Health Enterprises IPO

The total issue size is Rs 9,275 crore, of which Rs 8,000 crore is a fresh issue, and the remaining Rs 1,275 crore is an offer for sale.

The funds raised through the fresh issue through an IPO will be used for the following objectives.

• Prepayment or Repayment of Outstanding Borrowings by the company (Rs 5,552.75 crore)

• Funding the purchase consideration for the acquisition of the remaining minority equity stake in step-down subsidiary, Sahyadri Hospitals Private Limited (SHPL) (Rs 574 crore)

• The remaining funds will be used for General Corporate Purposes.

Manipal Health Enterprises IPO Details

IPO Dates

Manipal Health Enterprises IPO will be open for subscription from July 29, 2026, to July 31, 2026. The allotment of shares to investors will take place on August 03, 2026, and the company is expected to be listed on the NSE and BSE on August 05, 2026.

IPO Issue Price

Manipal Health Enterprises is offering its shares in the price band of Rs 560 to Rs 590 per share. This means you would require an investment of Rs 14,750 per lot (25 shares) if you are bidding for the IPO at the upper price band.

IPO Size

Manipal Health Enterprises is launching a total issue of Rs 9,275 crore, out of which the fresh issue is worth Rs 8,000 crore and the offer for sale is worth Rs 1,275 crore.

IPO Allotment Status

Investors who applied for the IPO can check their IPO allotment status on August 03, 2026, through the registrar's website, Kfin Technologies Limited, BSE, NSE, or through their stockbroker platform.

IPO Listing Date

The shares of Manipal Health Enterprises are expected to be listed on the NSE and BSE on August 05, 2026.

IPO Application Link

Open demat account with Rupeezy today and enjoy a seamless experience when applying for the IPO. With an easy-to-use platform, Rupeezy makes the IPO application process quick and hassle-free.

Apply for Manipal Health Enterprises IPO